Advanced Urothelial Carcinoma
Advertisement
These findings highlight the need for continued development and refinement of standardized HER2 testing methods.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
Enfortumab + pembrolizumab showed improved responses over chemo in untreated la/mUC, per updated EV-302 results.
Nivolumab + ipilimumab provided a favorable landmark OS in cisplatin-ineligible patients with unresectable or metastatic UC.
Researchers evaluated the use of disitamab vedotin with toripalimab in improving survival in patients with advanced UC.
Consolidative surgery after EVP shows feasibility and strong pathologic response rates in advanced urothelial carcinoma.
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Dr. Grivas provides perspective of the long-term outcomes from the JAVELIN Bladder 100 trial as pertaining to older patients.
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
EV with erdafitinib is a feasible combination with the ability to provide promising antitumor activity in mUC.
The indication for SG as a treatment for patients with pretreated aUC will be officially withdrawn by Gilead.
PIVOT-10 expanded on PIVOT-02 by further investigating BEMPEG with nivolumab in cisplatin-ineligible patients.
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.